Derek Thompson

Co-author, Abundance; Host, Plain English; Contributing Writer, The Atlantic
· tracked since Jun 2026
Calls
1
Win Rate
100.0%
return
+4.8%
Calls 1 1 Posts tracked · 0.0/day
Calls
7d 0
30d 0
90d 0
Win Rate 100% Long 1 Short 0
Win Rate
7d 100%
30d 100%
90d 100%
Average Return +4.8% Long Return +4.8% Short Return -
Average Return
7d +2.5%
30d +4.3%
90d +3.4%
Visual Insights Log in to see more
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jun 18
$1099.89
+4.8%
Eli Lilly's retatrutide will supercharge GLP-1 demand.
The self-optimization health trend is accelerating and GLP-1 demand will go crazy when Eli Lilly's third-generation GLP-1 drug retatrutide comes out; gym usage, peptide stacking, TRT, and related health behaviors are all rising.
GLP-1 / Obesity
Showing 1 of 1 calls · sorted by mentions

Derek Thompson has 1 trade ideas tracked on Buzzberg across 1 tickers since June 2026. Most covered: LLY.

Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology